Total
0
Shares
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald
CEO & Executive Chairman, Bob Proulx
Source: The Market Herald
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imagion Biosystems (IBX) has updated the market regarding its activities and cash flow during the December quarter
  • In early October, the healthcare company received approval from the Human Research Ethics Committee for its MagSense HER2 breast cancer study
  • This study will trial MagSense and its ability to detect early-stage breast cancer
  • Geoff Hollis was appointed Chief Financial Officer in mid-October, replacing Brain Conn
  • Finally, Imagion raised $5.6 million in November and used the funds to accelerate development and scale-up manufacturing
  • Throughout the quarter, Imagion burnt just over $1.49 million with the majority going towards research and development
  • As of December 31, the company had $13.2 million in available funding, enough to support operations for another 8.86 quarters if spending levels stay the same
  • Imagion is up 5.71 per cent on the market and shares are trading at 18.5 cents

Imagion Biosystems (IBX) has updated the market regarding its activities and cash flow during the December quarter.

Activities

In early October, the healthcare company received approval from the Human Research Ethics Committee (HREC) for its MagSense HER2 phase one breast cancer study.

MagSense is being trialled to effectively detect HER2 metastatic breast cancer in the early stages.

Metastatic breast cancer occurs when cancer spreads beyond the breast to other organs in the body, notably the bones, liver, lungs or brain. Despite this, it is still considered breast cancer.

Later on in the month, Geoff Hollis was appointed Chief Financial Officer, replacing Brain Conn.

Geoff took up this position on December 1, strengthening Imagion's management and leadership team for the next phase of growth.

In November, Imagion raised $5.6 million via an oversubscribed placement and used the funds to accelerate development and scale-up manufacturing and product development.

"2020 has been a breakout year for Imagion. After much diligence and hard work, we are delighted to have finished the year with our first in-human study established and open for enrolment," Executive Chairman and CEO Bob Proulx said.

"We are excited for what lies ahead in 2021, particularly as the MagSense HER2 breast cancer phase one study progresses and we explore further development areas including manufacturing scale-up and a larger pivotal study," he added.

Cash flow

Throughout the quarter, Imagion burnt through just over $1.49 million, primarily in the research and development, staff, corporate and administration cost categories.

As of December 31, the company had $13.2 million in available funding, enough to support operations for another 8.86 quarters if spending levels stay the same.

Imagion is up 5.71 per cent on the market and shares are trading at 18.5 cents at 2:09 pm AEDT.

IBX by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.